KRAS and non-small cell lung carcinoma: Dual inhibition of PI3K and MEK was tested in a panel of NSCLC lines (n=12) with the K-Ras (n=3), EGFR (n=3), ALK (n=3), or triple-negative (n=3) oncogenic genotypes.